Hao G Nguyen1, Derya Tilki1, Marc A Dall'Era1, Blythe Durbin-Johnson1, Joaquín A Carballido2, Thenappan Chandrasekar1, Thomas Chromecki3, Gaetano Ciancio4, Siamak Daneshmand5, Paolo Gontero6, Javier Gonzalez7, Axel Haferkamp8, Markus Hohenfellner9, William C Huang10, Estefania Linares Espinós2, Philipp Mandel11, Juan I Martinez-Salamanca2, Viraj A Master12, James M McKiernan13, Francesco Montorsi14, Giacomo Novara15, Sascha Pahernik9, Juan Palou16, Raj S Pruthi17, Oscar Rodriguez-Faba16, Paul Russo18, Douglas S Scherr19, Shahrokh F Shariat20, Martin Spahn21, Carlo Terrone22, Daniel Vergho21, Eric M Wallen17, Evanguelos Xylinas19,23, Richard Zigeuner3, John A Libertino24, Christopher P Evans1. 1. Department of Urology, UC Davis Medical Center, Sacramento, California, USA. 2. Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain. 3. Department of Urology, Medical University of Graz, Graz, Austria. 4. Miami Transplant Institute, University of Miami, Miami, FL, USA. 5. USC/Norris Comprehensive Cancer Center, Los Angeles, California, USA. 6. Department of Urology, A.O.U. San Giovanni Battista, University of Turin, Turin, Italy. 7. Department of Urology, Hospital Central de la Cruz Roja San José y Santa Adela, Madrid, Spain. 8. Department of Urology, University of Frankfurt, Frankfurt, Germany. 9. Department of Urology, University of Heidelberg, Heidelberg, Germany. 10. Department of Urology, New York University School of Medicine, New York, USA. 11. Institute of of Empirical Economic Research, University of Leipzig, Leipzig, Germany. 12. Department of Urology, Emory University, Atlanta, Georgia, USA. 13. Department of Urology, Columbia University College of Physicians and Surgeons, New York, USA. 14. Department of Urology, Hospital San Raffaele, University Vita-Salute, Milano, Italy. 15. University of Padua, Padua, Italy. 16. Department of Urology, Fundació Puigvert, Barcelona, Spain. 17. Department of Urology, UNC at Chappel Hill, Chapel Hill, North Carolina, USA. 18. Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 19. Department of Urology, Weill Cornell Medical Center, New York, USA. 20. Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. 21. University of Würzburg, Würzburg, Germany. 22. Division of Urology, Maggiore della Carita Hospital, University of Eastern Piedmont, Novara, Italy. 23. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. 24. Department of Urology, Lahey Clinic, Burlington, Massachusetts, USA.
Abstract
PURPOSE: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass. MATERIALS AND METHODS: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses. RESULTS: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study. CONCLUSIONS: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.
PURPOSE: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass. MATERIALS AND METHODS: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses. RESULTS: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study. CONCLUSIONS: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.
Authors: Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino Journal: Curr Urol Rep Date: 2014-05 Impact factor: 3.092
Authors: Candace F Granberg; Stephen A Boorjian; Hartzell V Schaff; Thomas A Orszulak; Bradley C Leibovich; Christine M Lohse; John C Cheville; Michael L Blute Journal: Urology Date: 2008-04-18 Impact factor: 2.649
Authors: Gaetano Ciancio; Samir P Shirodkar; Mark S Soloway; Alan S Livingstone; Michael Barron; Tomas A Salerno Journal: Ann Thorac Surg Date: 2010-02 Impact factor: 4.330
Authors: E Jason Abel; R Houston Thompson; Vitaly Margulis; Jennifer E Heckman; Megan M Merril; Oussama M Darwish; Laura-Maria Krabbe; Stephen A Boorjian; Bradley C Leibovich; Christopher G Wood Journal: Eur Urol Date: 2013-11-07 Impact factor: 20.096
Authors: Serban Mihai Balanescu; Dinu Valentin Balanescu; Teodora Donisan; Eric H Yang; Nicolas Palaskas; Juan Lopez-Mattei; Saamir Hassan; Peter Kim; Mehmet Cilingiroglu; Konstantinos Marmagkiolis; Biswajit Kar; Cezar Iliescu Journal: Curr Cardiol Rep Date: 2019-07-08 Impact factor: 2.931